FI3273955T3 - Hengityselinsairauksien hoito - Google Patents

Hengityselinsairauksien hoito

Info

Publication number
FI3273955T3
FI3273955T3 FIEP16767533.9T FI16767533T FI3273955T3 FI 3273955 T3 FI3273955 T3 FI 3273955T3 FI 16767533 T FI16767533 T FI 16767533T FI 3273955 T3 FI3273955 T3 FI 3273955T3
Authority
FI
Finland
Prior art keywords
inhibitor
use according
treatment
respiratory diseases
glucocorticoids
Prior art date
Application number
FIEP16767533.9T
Other languages
English (en)
Finnish (fi)
Inventor
Alastair Stewart
Christine Keenan
Trudi Harris
Original Assignee
Tianli Biotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901032A external-priority patent/AU2015901032A0/en
Application filed by Tianli Biotech Pty Ltd filed Critical Tianli Biotech Pty Ltd
Application granted granted Critical
Publication of FI3273955T3 publication Critical patent/FI3273955T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP16767533.9T 2015-03-23 2016-03-23 Hengityselinsairauksien hoito FI3273955T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015901032A AU2015901032A0 (en) 2015-03-23 Treatment of respiratory diseases
PCT/AU2016/050209 WO2016149756A1 (en) 2015-03-23 2016-03-23 Treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
FI3273955T3 true FI3273955T3 (fi) 2025-12-12

Family

ID=56976881

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16767533.9T FI3273955T3 (fi) 2015-03-23 2016-03-23 Hengityselinsairauksien hoito

Country Status (8)

Country Link
US (4) US10722513B2 (https=)
EP (2) EP4591936A3 (https=)
JP (2) JP6827948B2 (https=)
CN (3) CN107847480B (https=)
ES (1) ES3055494T3 (https=)
FI (1) FI3273955T3 (https=)
PT (1) PT3273955T (https=)
WO (1) WO2016149756A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847480B (zh) 2015-03-23 2021-06-25 墨尔本大学 呼吸性疾病的治疗
JP2016193861A (ja) * 2015-03-31 2016-11-17 国立大学法人山梨大学 マスト細胞活性化を抑制するための医薬組成物
TW201837027A (zh) * 2017-02-01 2018-10-16 以色列商以色列耶路撒冷希伯來大學伊索研究發展有限公司 吡唑衍生物及其用途
PT3619204T (pt) * 2017-05-03 2025-10-29 Tianli Biotech Pty Ltd Compostos para o tratamento de doenças respiratórias
WO2019090405A1 (pt) * 2017-11-11 2019-05-16 Carvalho Junior Mario Virgilio De Medicamento de ciclesonida para cura e prevenção da gripe causada pelo vírus influenza
JP7575099B2 (ja) * 2018-11-07 2024-10-29 ティアンリ バイオテック プロプライエタリ リミテッド 呼吸器疾患の処理のための新規な化合物
KR102253324B1 (ko) * 2019-11-27 2021-05-18 단디바이오사이언스 주식회사 호흡기 질환의 예방, 개선 또는 치료용 조성물
US11801304B2 (en) * 2020-02-19 2023-10-31 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
IL305165A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
US12600721B2 (en) 2021-02-19 2026-04-14 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
WO2022235621A1 (en) * 2021-05-03 2022-11-10 Thirona Bio, Inc. Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor
CN115792229B (zh) * 2022-01-28 2024-06-18 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用
WO2024091485A1 (en) * 2022-10-25 2024-05-02 The Regents Of The University Of California Compositions and methods for treating or preventing pulmonary fibrosis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
FI972970A7 (fi) * 1995-01-12 1997-09-11 Smithkline Beecham Corp Uusia yhdisteitä
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6598603B1 (en) 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
EP1257546A1 (en) * 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
CN1968716A (zh) * 2003-01-09 2007-05-23 阿里泽克药品公司 治疗肺疾病的方法
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1713473B1 (en) 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
WO2005103240A1 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with casein kinase 1, delta, isoform 1 (csnk1d iso 1)
CN101031568A (zh) * 2004-06-23 2007-09-05 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
JP2009514876A (ja) * 2005-11-03 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼのための化合物および組成物
WO2008094208A2 (en) 2006-08-02 2008-08-07 Northwestern University Protein kinase targeted therapeutics
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
AU2008211613B2 (en) * 2007-02-02 2013-05-23 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
US20090136427A1 (en) * 2007-09-18 2009-05-28 La Jolla Institute For Allergy And Immunology LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
EP2317849A4 (en) * 2008-06-26 2011-11-02 Inspire Pharmaceuticals Inc PROCESS FOR THE TREATMENT OF LUNG DISEASES WITH RHO KINASE INHIBITOR COMPOUNDS
EP2344126A1 (en) 2008-10-14 2011-07-20 Activaero GmbH Method for treatment of copd and other pulmonary diseases
FR2943058B1 (fr) * 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
SI2493876T1 (sl) * 2009-10-28 2014-04-30 Pfizer Inc. Derivati imidazola kot inhibitorji kazein-kinaze
US20120263715A1 (en) * 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
US9801853B2 (en) * 2010-04-06 2017-10-31 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells
EP2651405A2 (en) * 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
EP2589385A1 (en) * 2011-11-03 2013-05-08 Fundación Centro Nacional de Investigaciones Oncológicas Triple combination for the treatment of cancer
WO2014018691A1 (en) * 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Generation of airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres
CZ2012538A3 (cs) 2012-08-08 2014-02-19 Masarykova Univerzita Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie
JP5990862B2 (ja) 2012-10-01 2016-09-14 国立研究開発法人科学技術振興機構 承認予測装置、承認予測方法、および、プログラム
CN103784451A (zh) * 2012-10-31 2014-05-14 无锡蕾明视康科技有限公司 一种治疗抑郁症的药物
EP2935272B1 (en) * 2012-12-21 2017-02-22 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
JP6267231B2 (ja) 2012-12-21 2018-01-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
CA2937992A1 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
CN107847480B (zh) 2015-03-23 2021-06-25 墨尔本大学 呼吸性疾病的治疗
JP2016193861A (ja) 2015-03-31 2016-11-17 国立大学法人山梨大学 マスト細胞活性化を抑制するための医薬組成物
WO2017083971A1 (en) 2015-11-16 2017-05-26 University Of Manitoba Compositions and methods for treatment of influenza
EP3531830A4 (en) 2016-10-28 2020-08-26 University of Utah Research Foundation METHODS AND COMPOSITIONS FOR IDENTIFICATION AND TREATMENT OF PATIENTS WITH SMALL CELL LUNG CANCER
PT3619204T (pt) 2017-05-03 2025-10-29 Tianli Biotech Pty Ltd Compostos para o tratamento de doenças respiratórias
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
MX2021002652A (es) 2018-09-09 2021-09-23 Qanatpharma Ag Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.

Also Published As

Publication number Publication date
EP3273955B1 (en) 2025-11-12
ES3055494T3 (en) 2026-02-12
JP7169693B2 (ja) 2022-11-11
JP2021073232A (ja) 2021-05-13
US20230146291A1 (en) 2023-05-11
CN107847480A (zh) 2018-03-27
EP3273955A4 (en) 2019-05-01
JP2018509438A (ja) 2018-04-05
US20240245690A1 (en) 2024-07-25
US20180071291A1 (en) 2018-03-15
US11975005B2 (en) 2024-05-07
CN113350353A (zh) 2021-09-07
CN107847480B (zh) 2021-06-25
US20200345740A1 (en) 2020-11-05
EP4591936A2 (en) 2025-07-30
US10722513B2 (en) 2020-07-28
EP3273955A1 (en) 2018-01-31
US11564925B2 (en) 2023-01-31
WO2016149756A1 (en) 2016-09-29
EP4591936A3 (en) 2025-10-15
JP6827948B2 (ja) 2021-02-10
CN113350352B (zh) 2024-09-10
PT3273955T (pt) 2025-12-19
CN113350352A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
FI3273955T3 (fi) Hengityselinsairauksien hoito
EP3310392A4 (en) PETROLATUM-BASED DISTRIBUTION SYSTEMS AND FOR ACTIVE SUBSTANCES
EP4663636A3 (en) Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
JP2015147774A5 (https=)
MX2020002271A (es) Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
PL3207928T3 (pl) Preparat złożony, zawierający nową pochodną kwasu 3-(4-(benzyloksy)fenylo)heks-4-ynowego oraz inny składnik czynny, przeznaczony do zapobiegania lub leczenia chorób metabolicznych
MA45984B1 (fr) Polytherapie pour la copd
WO2015171526A3 (en) Tricyclic pyrazolopyridine compounds
TN2016000489A1 (en) Carboxamide derivatives.
PH12019501955A1 (en) Tri-cycle compound and applications thereof
PL3890767T3 (pl) Przeznaczone do inhalacji kompozycje do zastosowania w leczeniu chorób płuc
TN2016000491A1 (en) Carboxamide derivatives.
WO2015001541A3 (en) Pharmaceutical film composition
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MY182008A (en) Pharmaceutical formulations
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
JOP20190045A1 (ar) مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
TN2017000248A1 (en) Cgrp antagonist peptides
KR101790286B9 (ko) -3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물
HRP20211309T1 (hr) N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti